<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of opioids for postoperative pain control</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of opioids for postoperative pain control</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use of opioids for postoperative pain control</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Buys, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maniker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H44110978"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The use of multimodal, opioid sparing analgesia is a key concept and a guiding principle for perioperative pain management. Multimodal analgesia involves the use of two or more agents or techniques with differing mechanisms of action. Whereas an overarching goal for pain management is to avoid excessive use of opioids, for patients expected to have moderate to severe pain, multimodal analgesia may require the use of opioids.</p><p>This topic will discuss the optimal use of perioperative opioids for opioid naïve patients who are in the hospital (post anesthesia care unit [PACU] or inpatients). An overall approach to perioperative pain management, use of opioids for acute pain in the ambulatory setting, and management of acute pain in patients who are opioid dependent are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127173.html" rel="external">"Approach to the management of acute perioperative pain in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/108806.html" rel="external">"Management of acute pain in opioid naïve adults in the ambulatory setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a> and  <a class="medical medical_review" href="/d/html/121628.html" rel="external">"Management of acute pain in adults with opioid use disorder"</a>.)</p><p></p><p class="headingAnchor" id="H871122713"><span class="h1">ROLE OF OPIOIDS IN ACUTE PAIN MANAGEMENT</span><span class="headingEndMark"> — </span>Opioids should be used along with non-opioid analgesic techniques and medications, and only added when those strategies are insufficient. Opioids are associated with short-term side effects (ie, respiratory depression, excessive sedation, nausea and vomiting, pruritus, urinary retention, constipation) and long-term adverse effects (ie, tolerance, dependence, opioid induced hyperalgesia, sexual dysfunction, mood disorders, or withdrawal upon conclusion of therapy) and possible opioid misuse and/or use disorder [<a href="#rid1">1-6</a>]. (See  <a class="medical medical_review" href="/d/html/120966.html" rel="external">"Risk of long term opioid use and misuse after prescription of opioids for pain"</a>.)</p><p>Opioids are commonly overprescribed after surgery, and many patients do well with minimal postoperative opioids. Emerging data suggest that non-opioid analgesics may be as or more effective than opioids for treating acute pain in many patients [<a href="#rid7">7-17</a>]. (See  <a class="medical medical_review" href="/d/html/108806.html" rel="external">"Management of acute pain in opioid naïve adults in the ambulatory setting", section on 'The decision to prescribe opioids'</a>.)</p><p class="headingAnchor" id="H974025162"><span class="h1">BASIC PRINCIPLES FOR PERIOPERATIVE OPIOID USE</span><span class="headingEndMark"> — </span>Basic principles for the use of opioids for perioperative pain are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of multi-modal analgesia, opioids should be the last medication to be used and the first to be stopped.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional goals (eg, the ability to rest/sleep, to take deep breaths and cough, and to participate in physical therapy) should be used as endpoints rather than a particular pain score.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain after surgery can vary widely in the course of the day from minimal pain at rest to severe pain after physical activity. For this reason, we typically prefer to use immediate release, short-acting opioids rather than extended release, long-acting formulations. The more rapid onset and offset of immediate opioids makes them easier to titrate to the need for analgesia, and to taper off opioids as pain subsides. Longer acting opioids may be appropriate for select patients with expected severe pain for more than a few days after major surgery. (See <a class="local">'Choice of opioid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-surgical pain should improve over the first days to weeks after surgery. Opioid requirements should likewise diminish.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opioids should be used for the shortest period of time possible. Absence of pain should not be the criterion for stopping opioids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative patient education should include expectations for postoperative pain and the appropriate use of opioids. This includes the plan to stop opioids prior to complete resolution of surgical pain, the importance of multimodal analgesia, and that opioids should not be used to treat concomitant non-surgical pain or as a sleep aid.</p><p></p><p class="headingAnchor" id="H423231952"><span class="h1">OPIOID METABOLISM</span><span class="headingEndMark"> — </span>Differences in opioid metabolism and excretion may be important considerations when choosing opioids.</p><p class="bulletIndent1"><span class="glyph">●</span>Most commonly used opioids undergo phase I metabolism in the liver via one of the cytochrome P450 (CYP) pathways (CYP3A4 and CYP2D6), with or without phase II glucuronidation. Exceptions include <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, which undergo only phase II glucuronidation  (<a class="graphic graphic_table graphicRef140310" href="/d/graphic/140310.html" rel="external">table 1</a>). Metabolism of opioids is reduced in patients with significant liver disease, and dosing intervals should be increased to avoid drug accumulation  (<a class="graphic graphic_table graphicRef90196" href="/d/graphic/90196.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opioids metabolized by CYP pathways (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>, <a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">tramadol</a>, <a class="drug drug_general" data-topicid="129220" href="/d/drug information/129220.html" rel="external">oliceridine</a>, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>) may interact with drugs that either inhibit or accelerate CYP metabolism  (<a class="graphic graphic_table graphicRef116164" href="/d/graphic/116164.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>). In addition, patients may have polymorphisms of CYP genes that affect drug metabolism. Polymorphisms may contribute to either diminished or absent metabolic enzymes or excessive metabolism, either of which can change the clinical effect of a given dose of opioid. Prevalence of CYP polymorphisms varies by ancestry. Variances in metabolism should be considered in patients who don’t respond to pro-drug opioids or have more of an effect than expected. (See  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some opioids have active or toxic metabolites. For some opioids, metabolites can accumulate in patients with kidney disease  (<a class="graphic graphic_table graphicRef100573" href="/d/graphic/100573.html" rel="external">table 5</a>). Recommended dosing for patients with kidney disease appears in the <a class="external" href="/drug-interactions">drug interaction program</a> (available through UpToDate) for individual drugs.</p><p></p><p>Examples of opioid metabolism include:</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Morphine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is metabolized into morphine-6-glucuronide, which has analgesic effects, and morphine-3-glucuronide, which does not have analgesic properties but can lead to brain excitability and seizures. Both metabolites are excreted in the urine. Thus morphine should be avoided, doses reduced, or dosing interval extended in patients with kidney dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Codeine</strong><strong> and </strong><strong>hydrocodone</strong><strong> </strong>–<strong> </strong>These are pro-drug opioids; they have only weak analgesic effects, but have metabolites with stronger mu opioid receptor (MOR) activity. Thus, patients who are rapid metabolizers may be at increased risk of respiratory depression or metabolite toxicity. Conversely, patients who have reduced metabolism may experience reduced analgesic benefit from these medications.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tramadol</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">Tramadol</a> is formulated as a racemic mixture that is metabolized via the CYP pathway. While the (+)-enantiomer of tramadol has some intrinsic MOR activity, its primary metabolite (+)-O-desmethyl-tramadol (M1) is a much stronger MOR ligand. Similar to other CYP prodrug pathways, rapid and ultra-rapid metabolizers may experience stronger opioid effects while nonmetabolizers may experience limited efficacy. M1 is renally excreted. Reduce dose or do not use in patients with renal insufficiency. In addition to MOR activity, tramadol also acts as a serotonin reuptake inhibitor ([+]-enantiomer) and a norepinephrine reuptake inhibitor ([-]-enantiomer).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Meperidine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> is metabolized to normeperidine (excreted in the urine), which has weak analgesic effects but can precipitate seizures. Meperidine should only be used for short term analgesia, if at all, and is contraindicated in patients with kidney dysfunction. (See  <a class="medical medical_review" href="/d/html/93774.html" rel="external">"Management of chronic pain in advanced chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/93774.html" rel="external">"Management of chronic pain in advanced chronic kidney disease", section on 'Drugs that should be avoided'</a>.)</p><p></p><p class="headingAnchor" id="H3623399103"><span class="h1">ASSESSING PAIN</span><span class="headingEndMark"> — </span>Visual analog scales or other numeric pain scales are commonly used parameters for opioid orders. While these are helpful to establish objective outcomes and as a measure to assess change after administering a therapy, we find them to be unreliable as the only determinant for opioid use and dosing. We prefer to base opioid use on functional outcomes (eg, resting comfortably, able to breathe deeply and cough, able to complete physical therapy).</p><p>Opioids should be held for patients with respiratory depression or who are excessively sedated, regardless of pain level parameters. For example, a patient who reports a pain level at 7 out of 10, but appears sedated or has a low respiratory rate, should not receive further opioid therapy until those side effects have resolved. (See <a class="local">'Oral dose adjustments'</a> below.)</p><p>Acute pain assessment is discussed separately. (See  <a class="medical medical_review" href="/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults", section on 'Postoperative monitoring for pain control and side effects'</a>.)</p><p class="headingAnchor" id="H4070132562"><span class="h1">TREATING PAIN IN THE POSTANESTHESIA CARE UNIT (PACU)</span><span class="headingEndMark"> — </span>It is not uncommon for patients to experience postoperative pain while still in the PACU. Oral opioids can be administered in the PACU to patients who are awake enough to safely take oral medication, and who can tolerate oral intake (ie, no nausea and vomiting, no NPO [nil per os] orders). For patients who will receive oral opioids after discharge from the PACU, they may be initiated while the patient is still in the PACU.</p><p>For patients with severe pain, intravenous (IV) opioids are typically used to initially control pain. The most commonly used opioids in this setting are <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, and <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>. In practice, we usually order both fentanyl and hydromorphone to be available in the PACU in titratable doses. We use fentanyl for rapid onset and short duration of action, and hydromorphone for patients who require a longer duration of action  (<a class="graphic graphic_table graphicRef140311" href="/d/graphic/140311.html" rel="external">table 6</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fentanyl</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> has a very rapid onset and a shorter duration of action than <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>. Fentanyl can be used to:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapidly control severe pain</p><p class="bulletIndent2"><span class="glyph">•</span>Treat pain while other nonopioid analgesic modalities are instituted or optimized (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal anti-inflammatory drugs [NSAIDs], epidural analgesia, peripheral nerve blocks)</p><p class="bulletIndent2"><span class="glyph">•</span>Establish adequate pain control while waiting for oral opioids to take effect</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydromorphone</strong><strong> </strong>–<strong> </strong>We administer <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> for patients who will benefit from a longer duration of action than <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> and who cannot take oral medications. This includes patients in whom regional anesthesia techniques (eg, epidural, peripheral nerve blocks) are not options. We prefer hydromorphone rather than <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> because hydromorphone has similar onset and duration of action as morphine with fewer side effects or concern for active metabolites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is an alternative to <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> for an opioid with a longer duration of action, but is associated with histamine release, and may cause pruritus, sedation, and/or hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> is commonly used to treat postoperative shivering, but should not be used for analgesia due to low efficacy and relatively high-risk profile compared with other opioids.</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9347" href="/d/drug information/9347.html" rel="external">Alfentanil</a>, <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a>, and <a class="drug drug_general" data-topicid="9954" href="/d/drug information/9954.html" rel="external">sufentanil</a> are not typically used in the PACU setting due to their very short duration of action.</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="129220" href="/d/drug information/129220.html" rel="external">Oliceridine</a> is a recently approved opioid for IV use that may be useful in the PACU and may have a lower risk of opioid-related side effects compared with other commonly used opioids [<a href="#rid18">18</a>]. There is limited clinical experience with using oliceridine.</p><p></p><p class="headingAnchor" id="H24143392"><span class="h1">INPATIENT POSTOPERATIVE PAIN CONTROL</span></p><p class="headingAnchor" id="H1818751726"><span class="h2">Oral versus intravenous (IV) administration</span><span class="headingEndMark"> — </span>We suggest using oral rather than intravenous (IV) opioids whenever possible for hospitalized patients unless immediate pain control or rapid titration is necessary. This approach is consistent with guidelines for acute pain management [<a href="#rid19">19,20</a>]. Available data suggest that IV opioids do not provide superior postoperative analgesia compared with oral formulations, even for very painful surgery [<a href="#rid21">21-25</a>]. Oral formulations often cost less than using IV opioids and allow the patient to continue the same drug after discharge if necessary.</p><p>IV administration results in rapid rise in effect site concentration leading to faster relief but also may lead to more sedation, increased respiratory depression, and a stronger euphoric effect. In a single institution retrospective database study of over 31,700 patients who were treated with opioids in the emergency department, IV administration was associated with increased adverse events (ie, nausea, vomiting, hypotension, oxygen desaturation) compared with oral administration (10.7 versus 1.8 percent) [<a href="#rid26">26</a>]. Conclusions from this study are limited by lack of data on some comorbidities (eg, obesity, obstructive sleep apnea), lack of data on opioid doses used, and limitations inherent in database studies.</p><p>Many opioids can also be delivered via subcutaneous, intramuscular, transdermal, or transmucosal routes of administration. However, utility of these formulations in postsurgical settings is limited by variable absorption, delayed onset, pain during administration, and cost.</p><p class="headingAnchor" id="H1408726438"><span class="h2">Oral opioids</span></p><p class="headingAnchor" id="H3055570009"><span class="h3">Scheduled versus as needed dosing</span><span class="headingEndMark"> — </span>For patients with severe pain who are expected to need opioids for more than a few days, we usually prescribe them on a scheduled basis for the first two to three days, or longer if necessary, and then change to as needed administration. For other patients who need opioids, they should typically be ordered on an as-needed rather than a scheduled basis to avoid administration of unnecessary opioids and associated risks of excessive sedation or respiratory depression.</p><p>Postoperative opioid administration for patients who chronically use opioids differs, and is discussed separately. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p class="headingAnchor" id="H3128724806"><span class="h3">Choice of opioid</span><span class="headingEndMark"> — </span>The choice of opioids after surgery is impacted by patient factors (hepatic failure, renal insufficiency, altered cytochrome P450 [CYP] expression), potential medication interactions (CYP upregulation or downregulation, concomitant selective serotonin or norepinephrine reuptake inhibitors), and patient experience with opioids in the past. Patients can often convey positive and negative (nausea, pruritus, poor efficacy) experiences from prior use and such a history should be elicited  (<a class="graphic graphic_table graphicRef140310" href="/d/graphic/140310.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of action </strong>–<strong> </strong>The expected duration of action for each type of opioid is a rough estimate only. The duration of action is highly variable and is influenced by the dose, variations in metabolism, subjective patient experience, and combination with other therapies. Importantly, use of opioids along with nonopioid analgesics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or nonsteroidal anti-inflammatory drugs [NSAIDs]) is likely to increase the efficacy and duration of action, compared with use of opioids without those medications [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate release (IR) versus extended release/long acting (ER/LA) formulations </strong>–<strong> </strong>For<strong> </strong>most patients the author administers immediate release opioids rather than extended-release/long acting (ER/LA) formulations for acute pain in opioid naïve patients [<a href="#rid20">20,29-34</a>]. IR opioids are easier to titrate due to faster onset than ER/LA opioids and are easier to titrate off as pain lessens. However, less frequent dosing and longer duration of action of ER opioids may help patients to sleep.</p><p></p><p class="bulletIndent1">For some patients with severe pain and who require high doses of IR opioids, one contributor to this topic administers a low dose of ER/LA opioid to provide a background opioid level for the first few days after surgery, and adds as needed IR opioid to provide an option for self-titration. If ER/LA opioids are used, they should be the first opioids discontinued as pain improves. (See <a class="local">'Discontinuing opioids'</a> below.)</p><p></p><p class="bulletIndent1">All patients require close monitoring and dose adjustments, particularly during the first few days after surgery. (See <a class="local">'Oral dose adjustments'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination formulations </strong>–<strong> </strong>We avoid using combination formulations that include an opioid and <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> or <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>. Separate administration allows administration of the nonopioid medication on a fixed schedule regardless of the patient’s opioid utilization, without limitation by the maximum daily dose of the nonopioid. For this reason, we do not routinely use <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>, which is only available as a combination formulation in the United States.</p><p></p><p class="headingAnchor" id="H2786996762"><span class="h3">Oral opioid options</span><span class="headingEndMark"> — </span>Options for oral opioids for acute perioperative pain include the following  (<a class="graphic graphic_table graphicRef140310" href="/d/graphic/140310.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxycodone</strong><strong> </strong>–<strong> </strong>The most common oral opioid we prescribe after surgery is <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a>. It is typically well-tolerated, inexpensive, and does not require an active metabolite for effect. It is subject to drug interactions because it is metabolized by CYP2D6 and 3A4 to active and inactive metabolites. Oxycodone is excreted in the urine; doses should be reduced and dosing intervals increased in patients with kidney dysfunction. (See <a class="local">'Opioid metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">Oxycodone</a> is available in 5 mg tablets, which allow convenient dosing as low as 2.5 mg, and is available as an elixir.</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 5 to 10 mg orally every 3 to 4 hours as needed, maximum 15 mg per dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydromorphone</strong><strong> </strong>–<strong> </strong>Oral <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> is also typically well tolerated, does not have active metabolites, is inexpensive, and is available in oral tablet or elixir formulations. Doses should be reduced and dosing intervals increased in patients with kidney dysfunction.</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 2 to 4 mg orally every 3 to 4 hours as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tramadol</strong><strong> and </strong><strong>tapentadol</strong><strong> </strong>–<strong> </strong>These are mixed mechanism opioids, with both weak mu opioid receptor activity and norepinephrine reuptake inhibition.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10010" href="/d/drug information/10010.html" rel="external">Tramadol</a> also inhibits serotonin reuptake. Tramadol requires CYP2D6 metabolism to have the full mu opioid receptor effect, so there will be patients who report good efficacy and others that report very poor efficacy. It should be avoided in patients taking serotonergic drugs (eg, selective serotonin reuptake inhibitors [SSRIs], serotonin-norepinephrine reuptake inhibitors [SNRIs], or monoamine oxidase inhibitors [MAO-I]) due to risk of serotonin syndrome. Tramadol is sometimes called a “weak opioid”, but it is associated with similar adverse effects as other opioids, including risks of misuse and physiologic dependence.</p><p></p><p class="bulletIndent2">Usual dose for opioid naïve patients – 50 to 100 mg orally every 4 to 6 hours as needed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9511" href="/d/drug information/9511.html" rel="external">Tapentadol</a> has no active metabolites. It is not available as a generic formulation so tends to be more expensive than other options.</p><p></p><p class="bulletIndent2">Usual dose for opioid naïve patients – 50 to 100 mg orally every 4 to 6 hours as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is available in immediate-release and extended-release formulations as well as in elixir. In the immediate-release form, its lowest dose formulation is 15 mg, which limits its utility in opioid-naïve individuals. Morphine is associated with histamine release, pruritus, and sedation. It should be avoided in patients with kidney dysfunction due to potential accumulation of active or toxic metabolites. (See <a class="local">'Opioid metabolism'</a> above.)</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 10 mg orally every 3 to 4 hours as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Codeine</strong><strong> </strong>–<strong> </strong>We avoid using <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> because of wide interpatient variability in metabolism, unreliable analgesia, and related incidences of adverse events. (See <a class="local">'Opioid metabolism'</a> above.) In a 2015 review of 39 prior reviews (total of 467 studies) that evaluated the analgesic efficacy of single doses of 41 different analgesic drugs administered for postoperative pain, codeine was the least effective analgesic studied, with a number needed to treat for 50 percent pain relief of 12 (95% CI 8.4 – 18) for codeine 60 mg [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 15 to 60 mg orally every 4 to 6 hours as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fentanyl</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> is available in transmucosal (buccal and sublingual) formulations. Transmucosal formulations are absorbed rapidly and can be titrated to pain needs, though dosing is imprecise. These formulations may be useful for patients with time limited pain (eg, dressing changes), and as an alternative to IV administration in patients who cannot take oral medication (eg, with head and neck cancer) or with limited absorption (eg, short gut syndrome).</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Buccal lozenge 200 mcg over 15 minutes, may repeat once 30 minutes after the start of the lozenge as needed; subsequent dose may be administered ≥4 hours after initial dose</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Buccal tablet 100 mcg, may repeat once after 30 minutes; subsequent dose may be administered ≥4 hours after the initial dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methadone</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is a long acting mu opioid receptor agonist commonly used for pharmacotherapy for OUD, but it can also be used for pain control. When used for analgesia, it is dosed at approximately every eight hours, whereas it is dosed once daily for OUD. Some clinicians administer low-dose methadone for opioid naïve patients who undergo major surgical procedures and are expected to have severe pain and prolonged hospital stay. It is available in both oral and IV forms.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is unique among opioids in that it is also an antagonist at the N-methyl-D-aspartate (NMDA) receptor, which may improve analgesia compared with other opioids. Intraoperative use of methadone has been shown to improve post-surgical pain and reduce post-surgical opioid use in the first 24 hours after surgery [<a href="#rid35">35,36</a>]. There is little data available for its use in post-surgical pain management in opioid naïve patients.</p><p></p><p class="bulletIndent1">Disadvantages of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It can prolong the QT interval and has been implicated as a cause of drug induced torsades de pointes [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> has variable bioavailability and can be difficult to convert to and from other opioids and from IV to oral methadone. Calculating <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> milligram equivalent doses of methadone is not reliable at higher doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is subject to drug interactions, as it is metabolized by cytochrome P450 enzymes. In small non-repeated doses, the effective half-life of methadone is short (four to eight hours) due to redistribution. However, with repeated doses, the effective half-life may be as long as 22 to 48 hours.</p><p></p><p class="bulletIndent1">Due to the complexities associated with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> use, it should only be prescribed by clinicians familiar with its use and should usually not be continued after discharge from the hospital.</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 2.5 to 10 mg orally every 8 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buprenorphine</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is a mu opioid receptor agonist with high affinity for the receptor but low intrinsic activity, and is an antagonist at the kappa-opioid receptor. It is often used for pharmacotherapy for opioid use disorder (OUD), but may also be used to treat both acute and chronic pain. The doses used for pain are typically much lower than those that are used for OUD. As an example, the usual dose of the buccal film in opioid naïve patients is 75 mcg, versus a starting dose of 2 to 4 mg sublingual for OUD. For acute pain buccal film and IV formulations are available.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is associated with less opioid-induced hyperalgesia and may produce less respiratory depression than other long acting opioids. A systematic review and meta-analysis comparing buprenorphine with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> for acute pain demonstrated no difference in pain efficacy or analgesic duration [<a href="#rid38">38</a>], despite the prolonged half-life of buprenorphine. The only side effect that favored buprenorphine was less pruritus. There was no difference in all other outcomes, including respiratory depression.</p><p></p><p class="bulletIndent1">Usual dose for opioid naïve patients – 75 mcg buccal film every 12 to 24 hours.</p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for acute pain in patients with OUD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/121628.html" rel="external">"Management of acute pain in adults with opioid use disorder"</a>.)</p><p></p><p class="headingAnchor" id="H1938103087"><span class="h3">Oral dose adjustments</span><span class="headingEndMark"> — </span>It is not uncommon for patients to report unsatisfactory pain control or bothersome opioid related side effects when on opioid therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>For lack of sufficient analgesia, assuming non-opioid analgesics have been optimized, it is important to assess whether the analgesic level is inadequate all of the time or if the analgesia wears off prior to the next dose being due. (See <a class="local">'Assessing pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient does not experience sufficient relief at all after taking the opioid, it is reasonable to increase the dose as a first step (eg, increase <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> from 5 mg to 10 mg).</p><p class="bulletIndent2"><span class="glyph">•</span>If relief occurs but does not last long enough, keep the dose the same and decrease the dosing interval.</p><p class="bulletIndent2"><span class="glyph">•</span>If modest dose and/or interval adjustments do not provide adequate pain relief, options include switching to a different oral opioid at an equipotent dose, or administering IV opioids, rather than escalating further the dose of the same drug.</p><p class="bulletIndent2"><span class="glyph">•</span>For patients who continue to have severe pain, consider performing an epidural or peripheral nerve block (if not already in place), or where available, consult an acute pain service for consideration of advanced analgesic strategies (eg, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> infusion). (See  <a class="medical medical_review" href="/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For opioid-related side effects (eg, nausea, pruritus, constipation), we recommend switching to a different opioid, adjusting dose, or stopping opioid therapy altogether.</p><p></p><p class="headingAnchor" id="H2408410307"><span class="h2">IV opioids</span><span class="headingEndMark"> — </span>IV opioids may be administered by intermittent clinician bolus, patient-controlled analgesia (PCA), or in select circumstances by continuous infusion. Continuous IV infusion of opioids is rarely indicated in opioid naïve individuals other than when intubated or in end-of-life care and should only be used in a monitored setting (eg, intensive care unit [ICU]) with continuous pulse oximetry and end-tidal carbon dioxide monitoring. (See  <a class="medical medical_review" href="/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Opioid analgesics'</a>.)</p><p class="headingAnchor" id="H3030439005"><span class="h3">Patient controlled analgesia (PCA) versus clinician-delivered intermittent bolus</span><span class="headingEndMark"> — </span>Intravenous opioid boluses can be delivered by a nurse or by the patient with a PCA device. The PCA pump is programmed to allow the patient to self-administer small doses of opioid with a fixed lockout interval  (<a class="graphic graphic_table graphicRef140312" href="/d/graphic/140312.html" rel="external">table 7</a>).</p><p>PCA is a widely used modality for IV opioid administration in patients who are awake and capable of understanding and controlling the device. PCA reduces delay in access to pain medication compared with as needed clinician boluses and provides the patient more control of the timing of their doses.</p><p>In a 2015 meta-analysis of 49 randomized trials (3400 patients) that evaluated PCA without a background opioid infusion versus clinician-administered methods of opioid administration (ie, IV bolus or intermittent infusion, intramuscular, subcutaneous, oral), PCA improved patient satisfaction and reduced pain scores slightly (9 to 10 points less on a scale of 0 to 100) [<a href="#rid39">39</a>]. PCA modestly increased 24-hour opioid consumption (7 <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> milligram equivalents, 95% CI 1 to 13 mg), and increased the incidence of pruritus (15 versus 8 percent of patients), without a difference in other adverse effects, including respiratory depression.</p><p>Examples of situations in which IV opioid bolus dosing may be useful include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have breakthrough pain while taking oral opioids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first night after total knee arthroplasty, as it is not uncommon for a patient to get behind and experience severe pain when the spinal anesthetic wears off</p><p></p><p class="bulletIndent1">In this setting we typically cancel the IV opioid order the morning after surgery and use only oral opioids thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first night after surgery for patients who have postoperative nausea and vomiting (PONV), and who will take oral opioids once PONV resolves</p><p></p><p class="headingAnchor" id="H2187162625"><span class="h3">Patient controlled analgesia</span></p><p class="headingAnchor" id="H3777892838"><span class="h4">Pump settings</span><span class="headingEndMark"> — </span>There is wide inter-institution variability in PCA pump settings, without consensus on optimal settings. An example is shown in a table  (<a class="graphic graphic_table graphicRef140312" href="/d/graphic/140312.html" rel="external">table 7</a>).</p><p>PCA devices are commonly programmed to deliver the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A demand dose</p><p class="bulletIndent1"><span class="glyph">●</span>A lockout interval until the next demand dose can be given; should be long enough to allow the opioid to reach effect prior to allowing additional dosing and is different for various opioids</p><p class="bulletIndent1"><span class="glyph">●</span>The maximum number of patient demand doses per hour</p><p class="bulletIndent1"><span class="glyph">●</span>The maximum total dose in a specific time period (eg, one, two, or four hours); this includes patient administered doses, clinician administered boluses, and basal infusion</p><p></p><p>Many PCA devices allow for clinician-administered doses to be given through the PCA device in addition to demand doses. With some devices the clinician-administered dose counts towards the maximum total dose programmed into the PCA pump.</p><p>The routine use of a continuous background infusion for PCA is<strong> not</strong> recommended and should be limited to carefully selected patients who are opioid tolerant, receiving end-of-life care, and/or receiving care in an ICU. A continuous infusion delivers opioid whether or not the patient is in pain and whether or not the patient is awake. Continuous infusion is associated with increased risk of respiratory depression in adults, but may be less of a concern in children.</p><p class="bulletIndent1"><span class="glyph">●</span>One retrospective study comparing a <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> PCA with or without basal infusion found that there was no difference in reported pain between groups despite significantly larger 24-hour opioid totals in the basal infusion group, but the incidence of adverse events was higher in the basal infusion group [<a href="#rid40">40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 14 randomized trials (796 patients, 674 adults, 122 children/adolescents), the addition of a background infusion to demand only PCA increased the risk of respiratory depression in adults (8.2 versus 0 percent, odds ratio 10.18, 95% CI 2.97 – 34.89) but not in children or adolescents [<a href="#rid41">41</a>]. Conclusions from this study are limited by the relatively small number of events and variable definition of respiratory depression.</p><p class="bulletIndent1"><span class="glyph">●</span>In another meta-analysis of 14 randomized trials of patients &lt;21 years of age (including three of the studies in the previously described meta-analysis), the addition of a continuous infusion did not improve pain scores or opioid consumption, and did not increase adverse events [<a href="#rid42">42</a>]. The quality of evidence was judged to be very low.</p><p></p><p class="headingAnchor" id="H4023563643"><span class="h4">Choice of opioid</span><span class="headingEndMark"> — </span>The most commonly used opioids for PCA are <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> and <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>  (<a class="graphic graphic_table graphicRef140312" href="/d/graphic/140312.html" rel="external">table 7</a>). Choice of opioid should be based on patient factors (eg, kidney or liver dysfunction, side effect tolerance) and hospital protocols, drug availability, and clinician familiarity. We prefer to use hydromorphone for most patients, since it is longer acting than fentanyl, and unlike morphine, can be used in patients with kidney dysfunction and does not cause histamine release.</p><p>Small randomized trials have found similar efficacy, side effects, and patient satisfaction with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> versus <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> PCA after surgery [<a href="#rid43">43,44</a>].</p><p><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> may be used in patients with liver or kidney disfunction or intolerance of <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>.</p><p><a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a>, <a class="drug drug_general" data-topicid="9954" href="/d/drug information/9954.html" rel="external">sufentanil</a>, and <a class="drug drug_general" data-topicid="9347" href="/d/drug information/9347.html" rel="external">alfentanil</a> are not used for postoperative analgesia because of their very short or ultrashort duration of action. <a class="drug drug_general" data-topicid="9608" href="/d/drug information/9608.html" rel="external">Meperidine</a> should not be used for PCA due to potential accumulation of normeperidine and the associated risk of seizures.</p><p><a class="drug drug_general" data-topicid="129220" href="/d/drug information/129220.html" rel="external">Oliceridine</a> is an opioid that was approved by the US Food and Drug Administration in 2020 for short term in-patient IV use, including PCA. Oliceridine is a G-protein selective agonist at the MOR with limited B-arrestin activity which, theoretically, may preserve analgesic efficacy while reducing respiratory and gastrointestinal tract related side effects. Phase III clinical trials demonstrated superior efficacy to placebo and similar efficacy to <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid45">45,46</a>]. Head-to-head prospective trials are still needed to compare efficacy and side effect profiles of oliceridine with other commonly used IV opioids.</p><p class="headingAnchor" id="H2628661670"><span class="h4">PCA dose adjustments</span><span class="headingEndMark"> — </span>PCA doses and intervals can be adjusted to meet the needs of the patient. For patients who are too sedated, or have evidence of respiratory depression, opioids should be held until these side effects resolve. Alternative non-opioid therapies should be considered and, if continued PCA use is required, doses should be decreased and/or lockout intervals increased.</p><p>We use the PCA history in addition to pain assessment to titrate PCA orders. For pain assessment we prefer assessment of functional pain parameters (eg, ability to cough, deep breathe, rest comfortably) rather than numerical pain scores. (See <a class="local">'Assessing pain'</a> above.) PCA use data can be obtained from review of the PCA device history and/or nursing record. The PCA history should provide the number of attempted patient actuations (records when the button is pushed even if a dose isn’t given due to device lockout), the number of delivered doses, and the total dose of medication delivered.</p><p>When adjusting PCA orders for pain it is usually preferable to change one parameter at a time (ie, demand dose or lockout interval) rather than both. In general, when adjusting PCA orders to improve analgesia or function, we consider the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For the patient who gets relief from the demand dose, but repeatedly activates the pump towards the end of the lockout interval, decrease the lockout interval (eg, reduce from 12 minutes to 10).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the patient who does not get relief from the demand dose (consistent repeated actuations) increase the demand dose.</p><p></p><p>Other aspects of the PCA history may be useful as well. As an example, if a PCA history shows no patient PCA attempts overnight but frequent attempts when the patient awakens, possible explanations may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>If in the morning the patient is showing signs of pain (eg, grimacing with movement and doesn’t want to cough), the patient may have adequate analgesia at rest, but increased pain with movement. This could also mean the patient got behind on self-administered dosing when asleep and now has severe pain. A clinician administered dose can be helpful to catch up without needing to change PCA settings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If in the morning the patient moves easily and has a strong cough and incentive spirometry, or is sedated, this may indicate PCA use for reasons other than pain such as patient anxiety. In this case, we typically reduce the dose and/or increase the interval while maximizing non-opioid therapies.</p><p></p><p>For opioid-naïve patients who do not receive relief with modest adjustments to PCA dose and interval, additional options include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Ensure non-opioid analgesic strategies are optimized (eg, local therapy as appropriate [ice, elevation, compression], <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal anti-inflammatory drugs)</p><p class="bulletIndent1"><span class="glyph">●</span>Change opioid to different type at equipotent dose</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for surgical causes of pain (eg, compartment syndrome, infection, anastomotic leak causing peritonitis, etc)</p><p class="bulletIndent1"><span class="glyph">●</span>Consult the acute pain service for possible regional anesthesia techniques, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> or <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> infusion. (See  <a class="medical medical_review" href="/d/html/133187.html" rel="external">"Nonopioid pharmacotherapy for acute pain in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3074290682"><span class="h3">Clinician boluses</span><span class="headingEndMark"> — </span>Clinician-administered IV dosing can be useful for patients who are not able to use a PCA device. Since nurses usually administer clinician boluses, orders are typically written for intervals of at least one to two hours  (<a class="graphic graphic_table graphicRef140313" href="/d/graphic/140313.html" rel="external">table 8</a>). We do not endorse the use of IV opioid boluses solely as a sleep aid at night.</p><p class="headingAnchor" id="H4265932814"><span class="h2">Transition from IV to oral opioid</span><span class="headingEndMark"> — </span>Transition to oral opioid formulations should occur as soon as the patient can tolerate oral medications. Nonopioid analgesics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal anti-inflammatory drugs) should be continued while switching from IV to oral opioids.</p><p>When switching from PCA to oral opioids, the following is a reasonable strategy used by one contributor to this topic:</p><p class="bulletIndent1"><span class="glyph">●</span>Discuss the plan to convert to oral opioids with the patient.</p><p class="bulletIndent1"><span class="glyph">●</span>Assess 24 hour opioid use for the past 24 hours; convert to equivalent oral opioid dose.</p><p class="bulletIndent1"><span class="glyph">●</span>Prescribe 50 percent of the total equivalent dose, divided into 6 oral doses every 3 to 4 hours as needed.</p><p class="bulletIndent1"><span class="glyph">●</span>Leave the PCA in place for 6 hours after the first oral opioid dose is administered, reassess usage at that time, and titrate oral opioid as necessary.</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue PCA device.</p><p></p><p class="headingAnchor" id="H260498755"><span class="h2">Discontinuing opioids</span><span class="headingEndMark"> — </span>For all patients who receive more than a few doses of postoperative opioids, a plan for tapering and stopping opioids should be in place. For most patients who require postoperative opioids, they can be reduced within two to four days of surgery. Nonopioid analgesics should be continued while tapering and stopping opioids.</p><p>For patients who receive opioids round the clock for very painful surgery, after a few days we change to as needed administration, and suggest creating a schedule for tapering by progressively reducing the opioid dose and increasing the dosing interval. A reasonable strategy is to reduce the total opioid dose by 20 to 30 percent every 1 to 2 days until cessation. A taper to discontinuation may reduce the risk of opioid withdrawal and may avoid chronic opioid use. Patients who are discharged with an opioid prescription should receive specific instructions for reducing and stopping opioid use.</p><p class="headingAnchor" id="H2365864204"><span class="h1">OPIOID SIDE EFFECTS AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Opioid related side effects occur in as many as 79 percent of patients who receive opioids for acute pain [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H3612600460"><span class="h2">Common side effects and complications</span><span class="headingEndMark"> — </span>Common side effects include constipation, sedation, and nausea and vomiting. Other side effects include dizziness, weakness, fatigue, urinary retention, pruritus, hypotension, delirium, and respiratory depression.</p><p>The first step to avoid opioid-related adverse events is to limit the use and dose of opioids. Changing the type of opioid may help with some side effects (eg, nausea or pruritus), but is less likely to relieve constipation. We prescribe stool softeners/laxatives and antiemetics for all patients who receive opioids.</p><p class="headingAnchor" id="H4007521893"><span class="h2">Respiratory depression</span><span class="headingEndMark"> — </span>Opioid induced respiratory depression (OIRD) is possible in any patient who receives opioids, and can result in severe morbidity or death. The incidence of (OIRD) after surgery is unknown; the reported rate varies widely depending on the definition used. Examples of studies of OIRD are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In one literature review, the incidence of respiratory depression in patients using PCA after surgery varied from 1.2 percent when assessed by observed respiratory rate, to 11.5 percent using oxygen desaturation by pulse oximetry [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective international study of 1335 patients who received parenteral opioids and were monitored for a median of 24 hours with continuous capnography and pulse oximetry, 46 percent of patients had at least one respiratory depression event [<a href="#rid50">50</a>]. Respiratory depression was defined as respiratory rate ≤5 breaths/minute, oxygen saturation ≤85%, or end-tidal carbon dioxide ≤15 or ≥60 mm Hg for ≥3 minutes; apnea lasting &gt;30 seconds; or any respiratory opioid-related adverse event.</p><p class="bulletIndent1"><span class="glyph">●</span>Using another indicator of respiratory depression, in one study <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> was administered to up to 0.7 percent of patients who receive postoperative <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> [<a href="#rid51">51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a metaanalysis of 29 studies (1914 patients) that compared PCA to other methods of postoperative opioid administration (eg, intramuscular, IV bolus, subcutaneous), there was not a significant difference in the incidence of postoperative respiratory depression (2.3 versus 2.0 percent, respectively) [<a href="#rid39">39</a>].</p><p></p><p>Risk factors for OIRD include opioid naïve status, older age, obstructive sleep apnea, severe obesity, postoperative status, receipt of other sedating medications, male sex, congestive heart failure, and smoking [<a href="#rid50">50,52-57</a>]. Enhanced monitoring (eg, continuous pulse oximetry, continuous capnography, and telemetry) should be considered for patients with these risk factors. Concomitant use of other sedating medications (eg, benzodiazepines) should be avoided.</p><p class="headingAnchor" id="H2781591132"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Despite the known risks associated with OIRD after surgery, the optimal methods for monitoring patients receiving systemic opioids have not been established. The Anesthesia Patient Safety Foundation (APSF), several other medical societies, and regulatory agencies have issued guidance with varying degrees of specificity for patients receiving parenteral opioids [<a href="#rid19">19,52,58-61</a>]. Though oral opioids are increasingly used for inpatients who have acute pain, there are no standards for the monitoring of patients receiving oral opioids.</p><p>We follow the APSF recommendation that all patients receiving parenteral opioids be monitored by continuous pulse oximetry and telemetry, in addition to interval nursing assessments of vital signs, pain, sedation, and respiratory function. In addition, we use continuous pulse oximetry and telemetry for at least 24 hours for patients with severe obesity or severe sleep apnea (obstructive and/or mixed) who are receiving oral opioid therapy.</p><p>Examples of recommendations for monitoring patients who receive opioids include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The Center for Medicare and Medicaid Services (CMS) guidelines for the monitoring of patients receiving opioids specify that hospitals must have policies and procedures related to the use of high-alert medications, including IV opioids for post-operative patients [<a href="#rid58">58</a>]. These policies must address patient risk assessment, monitoring frequency and duration, and monitoring methods. At a minimum, vital signs, pain level, respiratory status, and sedation level must be monitored.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Anesthesia Patient Safety Foundation (APSF) recommends that <strong>all </strong>hospitalized patients receiving parenteral opioids should be monitored by continuous pulse oximetry, preferably with centralized telemetry, in combination with intermittent nursing assessment [<a href="#rid59">59,60</a>]. Patients who require supplemental oxygen should also be monitored with capnography or other modalities that measure the adequacy of ventilation.</p><p></p><p class="headingAnchor" id="H699125235"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118304.html" rel="external">"Society guideline links: Acute pain management"</a>.)</p><p class="headingAnchor" id="H120813379"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Opioids should be used as part of multimodal analgesia, should be discontinued prior to nonopioid analgesics, and should be used for the shortest period of time at the lowest effective dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should be educated on the expectations for postoperative pain and appropriate use of opioids, including functional goals, adequate analgesia rather than absence of pain, and the plan for stopping opioids. (See <a class="local">'Basic principles for perioperative opioid use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treating pain in the postanesthesia care unit (PACU)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral opioids can be used for patients who have moderate pain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with severe pain, intravenous (IV) opioids are typically used to achieve rapid analgesia. (See <a class="local">'Treating pain in the postanesthesia care unit (PACU)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids in the hospital after the PACU discharge </strong>–<strong> </strong>We suggest using oral rather than IV opioids whenever possible in patients who do not require immediate pain control or rapid titration (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). IV opioids may cause more side effects than oral formulations and do not provide superior postoperative analgesia. Oral formulations cost less and the same drug can be continued after discharge if necessary. (See <a class="local">'Oral versus intravenous (IV) administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral opioids</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of opioid </strong>– For most patients we suggest using immediate release opioids rather than extended release/long acting (ER/LA) opioid formulations (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). IR opioids are easier to titrate to the level of pain due to faster onset, and are easier to taper off as pain lessens. However, ER/LA opioids are a reasonable option for patients with severe pain, and their less frequent dosing and longer duration of action may help patients sleep. If extended release opioids are used they should be the first opioids discontinued as pain improves  (<a class="graphic graphic_table graphicRef140310" href="/d/graphic/140310.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">Methadone</a> is a long acting opioid that may be useful for patients with severe pain expected to last several days. (See <a class="local">'Choice of opioid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IV opioids </strong>–<strong> </strong>For IV opioids, we suggest bolus administration (by clinician bolus or patient controlled analgesia), rather than use of continuous infusion (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Continuous infusion is associated with increased risk of respiratory depression, and should only be used for selected patients in a monitored setting (eg, intensive care unit)  (<a class="graphic graphic_table graphicRef140310" href="/d/graphic/140310.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PCA versus clinician bolus </strong>–<strong> </strong>PCA reduces delay in access to pain medication, gives the patient control over timing of the dose, and does not increase side effect, including respiratory depression. Clinician boluses may be useful for patients who have breakthrough pain while taking oral opioids or who have a temporary need for IV opioids before using oral formulations. (See <a class="local">'Patient controlled analgesia (PCA) versus clinician-delivered intermittent bolus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PCA opioid </strong>–<strong> </strong>The choice of PCA opioid should be based on patient factors and institutional preference. Efficacy and side effects are similar with <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> versus <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>  (<a class="graphic graphic_table graphicRef140312" href="/d/graphic/140312.html" rel="external">table 7</a>). (See <a class="local">'Patient controlled analgesia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition from IV to oral opioid </strong>–<strong> </strong>Transition to oral opioid formulations should occur as soon as the patient can tolerate oral medications. Nonopioid analgesics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal anti-inflammatory drugs) should be continued while switching from IV to oral opioids. (See <a class="local">'Transition from IV to oral opioid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuing opioids </strong>– Opioids should be stopped as soon as possible after surgery. For most patients, opioids can be reduced within two to four days after surgery. For all patients who receive postoperative opioids, a plan for tapering and stopping opioids should be in place. The taper schedule should usually include reductions in both dose and dose interval. (See <a class="local">'Discontinuing opioids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioid induced respiratory depression (OIRD) </strong>–<strong> </strong>OIRD is possible in any patient who receives opioids and can result in severe morbidity or death. (See <a class="local">'Respiratory depression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All patients who receive opioids should be monitored for sedation and respiration, and patients who receive IV opioids should be monitored with pulse oximetry with telemetry. Patients with risk factors for respiratory depression (eg, severe obesity, severe obstructive sleep apnea) may require enhanced monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant use of other sedating medications (eg, benzodiazepines) should be avoided in patients who receive opioids.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev 2007; 11:35.</a></li><li><a class="nounderline abstract_t">Tang NKY, Stella MT, Banks PDW, et al. The effect of opioid therapy on sleep quality in patients with chronic non-malignant pain: A systematic review and exploratory meta-analysis. Sleep Med Rev 2019; 45:105.</a></li><li><a class="nounderline abstract_t">Hooten WM, Brummett CM, Sullivan MD, et al. A Conceptual Framework for Understanding Unintended Prolonged Opioid Use. Mayo Clin Proc 2017; 92:1822.</a></li><li><a class="nounderline abstract_t">Santosa KB, Lai YL, Brummett CM, et al. Higher Amounts of Opioids Filled After Surgery Increase Risk of Serious Falls and Fall-Related Injuries Among Older Adults. J Gen Intern Med 2020; 35:2917.</a></li><li><a class="nounderline abstract_t">Howard R, Gunaseelan V, Brummett C, et al. New Persistent Opioid Use After Inguinal Hernia Repair. Ann Surg 2022; 276:e577.</a></li><li><a class="nounderline abstract_t">Chua KP, Hu HM, Waljee JF, et al. Persistent Opioid Use Associated With Dental Opioid Prescriptions Among Publicly and Privately Insured US Patients, 2014 to 2018. JAMA Netw Open 2021; 4:e216464.</a></li><li><a class="nounderline abstract_t">Anderson M, Hallway A, Brummett C, et al. Patient-Reported Outcomes After Opioid-Sparing Surgery Compared With Standard of Care. JAMA Surg 2021; 156:286.</a></li><li><a class="nounderline abstract_t">Mitchell A, McCrea P, Inglis K, Porter G. A randomized, controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine (Tylenol 3) after outpatient breast surgery. Ann Surg Oncol 2012; 19:3792.</a></li><li><a class="nounderline abstract_t">Weinheimer K, Michelotti B, Silver J, et al. A Prospective, Randomized, Double-Blinded Controlled Trial Comparing Ibuprofen and Acetaminophen Versus Hydrocodone and Acetaminophen for Soft Tissue Hand Procedures. J Hand Surg Am 2019; 44:387.</a></li><li><a class="nounderline abstract_t">Fleischman AN, Tarabichi M, Foltz C, et al. Cluster-Randomized Trial of Opiate-Sparing Analgesia after Discharge from Elective Hip Surgery. J Am Coll Surg 2019; 229:335.</a></li><li><a class="nounderline abstract_t">Sim V, Hawkins S, Gave AA, et al. How low can you go: Achieving postoperative outpatient pain control without opioids. J Trauma Acute Care Surg 2019; 87:100.</a></li><li><a class="nounderline abstract_t">Mitchell A, van Zanten SV, Inglis K, Porter G. A randomized controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine after outpatient general surgery. J Am Coll Surg 2008; 206:472.</a></li><li><a class="nounderline abstract_t">Nauta M, Landsmeer ML, Koren G. Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials. Am J Surg 2009; 198:256.</a></li><li><a class="nounderline abstract_t">Helmerhorst GTT, Zwiers R, Ring D, Kloen P. Pain Relief After Operative Treatment of an Extremity Fracture: A Noninferiority Randomized Controlled Trial. J Bone Joint Surg Am 2017; 99:1908.</a></li><li><a class="nounderline abstract_t">Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database Syst Rev 2015; :CD008659.</a></li><li><a class="nounderline abstract_t">Mark J, Argentieri DM, Gutierrez CA, et al. Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery. JAMA Netw Open 2018; 1:e185452.</a></li><li><a class="nounderline abstract_t">Chang AK, Bijur PE, Esses D, et al. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial. JAMA 2017; 318:1661.</a></li><li><a class="nounderline abstract_t">Dahan A, van Dam CJ, Niesters M, et al. Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine. Anesthesiology 2020; 133:559.</a></li><li><a class="nounderline abstract_t">Herzig SJ, Mosher HJ, Calcaterra SL, et al. Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults: A Consensus Statement From the Society of Hospital Medicine. J Hosp Med 2018; 13:263.</a></li><li><a class="nounderline abstract_t">Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016; 17:131.</a></li><li><a class="nounderline abstract_t">Ruetzler K, Blome CJ, Nabecker S, et al. A randomised trial of oral versus intravenous opioids for treatment of pain after cardiac surgery. J Anesth 2014; 28:580.</a></li><li><a class="nounderline abstract_t">Niklasson B, Arnelo C, Öhman SG, et al. Oral oxycodone for pain after caesarean section: A randomized comparison with nurse-administered IV morphine in a pragmatic study. Scand J Pain 2015; 7:17.</a></li><li><a class="nounderline abstract_t">Rothwell MP, Pearson D, Hunter JD, et al. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study. Br J Anaesth 2011; 106:865.</a></li><li><a class="nounderline abstract_t">Ackerman AL, O'Connor PG, Doyle DL, et al. Association of an Opioid Standard of Practice Intervention With Intravenous Opioid Exposure in Hospitalized Patients. JAMA Intern Med 2018; 178:759.</a></li><li><a class="nounderline abstract_t">Cheung CW, Ching Wong SS, Qiu Q, Wang X. Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials. Pain Physician 2017; 20:SE33.</a></li><li><a class="nounderline abstract_t">Daoust R, Paquet J, Lavigne G, et al. Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective study. Pain Res Manag 2015; 20:23.</a></li><li><a class="nounderline abstract_t">Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; :CD002763.</a></li><li><a class="nounderline abstract_t">Derry S, Derry CJ, Moore RA. Single dose oral ibuprofen plus oxycodone for acute postoperative pain in adults. Cochrane Database Syst Rev 2013; :CD010289.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. Available at: https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf (Accessed on September 22, 2021).</li><li><a class="nounderline abstract_t">Webster LR. Eight principles for safer opioid prescribing. Pain Med 2013; 14:959.</a></li><li class="breakAll">FDA’s Opioid Analgesic REMS Education Blueprint for Health Care
Providers Involved in the Treatment and Monitoring of Patients with Pain. U.S. Food and Drug Administration. Available at: https://www.fda.gov/media/99496/download (Accessed on February 06, 2023).</li><li class="breakAll">PS41(G) Position statement on acute pain management 2022. Australian and New Zealand College Of Anaesthetists. Available at: https://www.anzca.edu.au/getattachment/558316c5-ea93-457c-b51f-d57556b0ffa7/PS41-Guideline-on-acute-pain-management (Accessed on February 06, 2023).</li><li><a class="nounderline abstract_t">Cantrill SV, Brown MD, Carlisle RJ, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med 2012; 60:499.</a></li><li><a class="nounderline abstract_t">Levy N, Quinlan J, El-Boghdadly K, et al. An international multidisciplinary consensus statement on the prevention of opioid-related harm in adult surgical patients. Anaesthesia 2021; 76:520.</a></li><li><a class="nounderline abstract_t">D'Souza RS, Gurrieri C, Johnson RL, et al. Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis. Pain 2020; 161:237.</a></li><li><a class="nounderline abstract_t">Cheriyan T, Gaber M, Glenn T, et al. Effect of intraoperative methadone vs other opioids on postoperative outcomes: a meta-analysis of randomized controlled studies. Pain 2022; 163:e153.</a></li><li><a class="nounderline abstract_t">Romero J, Baldinger SH, Goodman-Meza D, et al. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise? J Interv Card Electrophysiol 2016; 45:37.</a></li><li><a class="nounderline abstract_t">White LD, Hodge A, Vlok R, et al. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth 2018; 120:668.</a></li><li><a class="nounderline abstract_t">McNicol ED, Ferguson MC, Hudcova J. Patient controlled opioid analgesia versus non-patient controlled opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2015; :CD003348.</a></li><li><a class="nounderline abstract_t">Jung H, Lee KH, Jeong Y, et al. Effect of Fentanyl-Based Intravenous Patient-Controlled Analgesia with and without Basal Infusion on Postoperative Opioid Consumption and Opioid-Related Side Effects: A Retrospective Cohort Study. J Pain Res 2020; 13:3095.</a></li><li><a class="nounderline abstract_t">George JA, Lin EE, Hanna MN, et al. The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: a meta-analysis. J Opioid Manag 2010; 6:47.</a></li><li><a class="nounderline abstract_t">Hayes J, Dowling JJ, Peliowski A, et al. Patient-Controlled Analgesia Plus Background Opioid Infusion for Postoperative Pain in Children: A Systematic Review and Meta-Analysis of Randomized Trials. Anesth Analg 2016; 123:991.</a></li><li><a class="nounderline abstract_t">Hong D, Flood P, Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 2008; 107:1384.</a></li><li><a class="nounderline abstract_t">Rapp SE, Egan KJ, Ross BK, et al. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 1996; 82:1043.</a></li><li><a class="nounderline abstract_t">Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty. Pain Pract 2019; 19:715.</a></li><li><a class="nounderline abstract_t">Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res 2019; 12:927.</a></li><li><a class="nounderline abstract_t">Daoust R, Paquet J, Cournoyer A, et al. Side effects from opioids used for acute pain after emergency department discharge. Am J Emerg Med 2020; 38:695.</a></li><li><a class="nounderline abstract_t">Hunold KM, Esserman DA, Isaacs CG, et al. Side effects from oral opioids in older adults during the first week of treatment for acute musculoskeletal pain. Acad Emerg Med 2013; 20:872.</a></li><li><a class="nounderline abstract_t">Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004; 93:212.</a></li><li><a class="nounderline abstract_t">Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial. Anesth Analg 2020; 131:1012.</a></li><li><a class="nounderline abstract_t">Shapiro A, Zohar E, Zaslansky R, et al. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth 2005; 17:537.</a></li><li><a class="nounderline abstract_t">Jarzyna D, Jungquist CR, Pasero C, et al. American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression. Pain Manag Nurs 2011; 12:118.</a></li><li class="breakAll">Pasero C, McCaffery M. Pain Assessment and Pharmacologic Management, 1st ed, Mosby Elseveir, 2011.</li><li><a class="nounderline abstract_t">Driver CN, Laporta ML, Bergese SD, et al. Frequency and Temporal Distribution of Postoperative Respiratory Depressive Events. Anesth Analg 2021; 132:1206.</a></li><li><a class="nounderline abstract_t">Overdyk FJ. Postoperative opioids remain a serious patient safety threat. Anesthesiology 2010; 113:259.</a></li><li><a class="nounderline abstract_t">Ozdilekcan C, Songur N, Berktaş BM, et al. Risk factors associated with postoperative pulmonary complications following oncological surgery. Tuberk Toraks 2004; 52:248.</a></li><li class="breakAll">Stoelting RK, Weinger MB. Dangers of postoperative opioids – is there a cure? Anesthesia Patient Safety Foundation Newsletter 2009; 24(2):25-26. Available at: https://www.apsf.org/article/dangers-of-postoperative-opioids-is-there-a-cure/ (Accessed on August 05, 2022).</li><li class="breakAll">Center for Clinical Standards and Quality/Survey &amp; Certification Group. Ref: S&amp;C: 14-15-Hospital. Requirements for Hospital Medication Administration, Particularly Intravenous (IV) Medications and Post-Operative Care of Patients Receiving IV Opioids. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-14-15.pdf (Accessed on September 14, 2022).</li><li class="breakAll">Executive Summary: Opioid-Induced Ventilatory Impairment (OIVI): Time for a change in the Monitoring Strategy for Postoperative PCA Patients. Anesthesia Patient Safety Foundation. Available at: https://www.apsf.org/videos/monitoring-for-opioid-induced-ventilatory-impairment-oivi-video/ (Accessed on August 05, 2022).</li><li class="breakAll">Weinger MB and Lee LA. No Patient Shall Be Harmed By Opioid-Induced Respiratory Depression. Anesthesia Patient Safety Foundation Newsletter. Available at: https://www.apsf.org/article/no-patient-shall-be-harmed-by-opioid-induced-respiratory-depression/ (Accessed on February 06, 2023).</li><li class="breakAll">Pain assessment and management standards for hospitals. The Joint Commission. Available at: https://www.jointcommission.org/-/media/tjc/documents/resources/patient-safety-topics/sentinel-event/r3_report_issue_11_pain_assessment_8_25_17_final.pdf (Accessed on August 05, 2022).</li></ol></div><div id="topicVersionRevision">Topic 134254 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17141540" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Opioids, sleep architecture and sleep-disordered breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31085434" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The effect of opioid therapy on sleep quality in patients with chronic non-malignant pain: A systematic review and exploratory meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108841" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Conceptual Framework for Understanding Unintended Prolonged Opioid Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32748343" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Higher Amounts of Opioids Filled After Surgery Increase Risk of Serious Falls and Fall-Related Injuries Among Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33065653" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : New Persistent Opioid Use After Inguinal Hernia Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33861332" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Persistent Opioid Use Associated With Dental Opioid Prescriptions Among Publicly and Privately Insured US Patients, 2014 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33502440" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Patient-Reported Outcomes After Opioid-Sparing Surgery Compared With Standard of Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22713999" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized, controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine (Tylenol 3) after outpatient breast surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502019" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Prospective, Randomized, Double-Blinded Controlled Trial Comparing Ibuprofen and Acetaminophen Versus Hydrocodone and Acetaminophen for Soft Tissue Hand Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31176028" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cluster-Randomized Trial of Opiate-Sparing Analgesia after Discharge from Elective Hip Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31259870" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : How low can you go: Achieving postoperative outpatient pain control without opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308218" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized controlled trial comparing acetaminophen plus ibuprofen versus acetaminophen plus codeine plus caffeine after outpatient general surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628064" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29135664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pain Relief After Operative Treatment of an Extremity Fracture: A Noninferiority Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414123" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646274" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114833" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32788558" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Benefit and Risk Evaluation of Biasedμ-Receptor Agonist Oliceridine versus Morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29624189" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Improving the Safety of Opioid Use for Acute Noncancer Pain in Hospitalized Adults: A Consensus Statement From the Society of Hospital Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26827847" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24375220" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A randomised trial of oral versus intravenous opioids for treatment of pain after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29911601" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral oxycodone for pain after caesarean section: A randomized comparison with nurse-administered IV morphine in a pragmatic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490024" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29799964" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Association of an Opioid Standard of Practice Intervention With Intravenous Opioid Exposure in Hospitalized Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28226340" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25664538" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588335" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801549" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single dose oral ibuprofen plus oxycodone for acute postoperative pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801549" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Single dose oral ibuprofen plus oxycodone for acute postoperative pain in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23841682" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Eight principles for safer opioid prescribing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23841682" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Eight principles for safer opioid prescribing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23841682" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Eight principles for safer opioid prescribing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010181" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33027841" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : An international multidisciplinary consensus statement on the prevention of opioid-related harm in adult surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613867" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intraoperative methadone administration and postoperative pain control: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34108437" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of intraoperative methadone vs other opioids on postoperative outcomes: a meta-analysis of randomized controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26589717" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576108" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26035341" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Patient controlled opioid analgesia versus non-patient controlled opioid analgesia for postoperative pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33262644" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of Fentanyl-Based Intravenous Patient-Controlled Analgesia with and without Basal Infusion on Postoperative Opioid Consumption and Opioid-Related Side Effects: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20297614" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27065359" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Patient-Controlled Analgesia Plus Background Opioid Infusion for Postoperative Pain in Children: A Systematic Review and Meta-Analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806056" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The side effects of morphine and hydromorphone patient-controlled analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610865" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162798" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at theμ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30881102" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at theµ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182367" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Side effects from opioids used for acute pain after emergency department discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033733" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Side effects from oral opioids in older adults during the first week of treatment for acute musculoskeletal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169738" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32925318" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297754" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21893302" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21893302" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857962" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Frequency and Temporal Distribution of Postoperative Respiratory Depressive Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20574235" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Postoperative opioids remain a serious patient safety threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15351938" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk factors associated with postoperative pulmonary complications following oncological surgery.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
